Intellectual Property - April 10, 2019
Additional patent protection for Oncopeptides
The US patent and trademark office has issued a notice that they intend to grant additional patents to Oncopeptides AB in the US. These patents protect, inter alia, the freeze-dried formulation. The patent protection extends to 2033. The freeze-dried preparation with melflufen is intended to be marketed at a future approval. Major key markets “We […]
Clinical Trials - March 4, 2019
New data from Oncopeptides
Data from the company’s Phase II HORIZON study and Phase I/II ANCHOR study evaluating the company’s novel candidate melflufen have been selected as poster presentations at the 2019 American Association for Cancer Research (AACR) Annual Meeting. The company’s data demonstrate tolerability and high level of activity associated with melflufen in relapsed/refractory multiple myeloma (RRMM) patients […]
Clinical Trials - June 14, 2017
First patient dosed in Oncopeptides’ study
Oncopeptides announces today that the first patient has been dosed in the pivotal phase III study OCEAN. The study is targeting Late-Stage Relapsed Refractory (RRMM) patients with Multiple Myeloma. It is designed as a head-to-head comparative study where the result will show whether Ygalo is more effective, just as effective, or less effective than the current standard […]
Business Award - May 18, 2017
Oncopeptides wins SwedenBIO Award 2017
Yesterday the 11th SwedenBIO Award was announced and the lucky winner was Oncopeptides. Oncopeptides received the award for its work in developing treatment against hematologic cancer. After several year of professional development work, Oncopeptides was able to present positive clinical phase II results with their drug candidate Ygalo in patients with Multiple Myeloma. Based on […]
Listing - February 8, 2017
Oncopeptides announce listing of its shares on Nasdaq
Oncopeptides has, together with HealthCap and Industrifonden (together the “Main Shareholders”), decided to, in order to further the company’s continued development of its product candidate Ygalo, carry out a broadening of its shareholder base through a new share issue of SEK 650 million (the “Offering”). The Board of Directors of Oncopeptides has applied for a […]
Clinical Trials - January 20, 2017
First patients enrolled in Oncopeptides study
Oncopeptides announces that the clinical development program is continuing according to plan and the company has recently initiated an additional Phase II clinical trial of Ygalo in combination with dexamethasone. The clinical trial is conducted in patients with late stage relapsed and refractory multiple myeloma (RRMM) that are refractory to treatments with pomalidomide and/or daratumumab. […]
